sethonno schreef:
SkySpam1
GTCB GTCB GTCB GTCB GTCB GTCB GTCB GTCB GTCB GTCB GTCB GTCB GTCB GTCB GTCB GTCB GTCB GTCB GTCB GTCB GTCB GTCB GTCB GTCB GTCB GTCB GTCB GTCB GTCB GTCB GTCB GTCB GTCB GTCB GTCB GTCB GTCB GTCB GTCB GTCB GTCB GTCB GTCB GTCB GTCB GTCB GTCB GTCB GTCB GTCB GTCB GTCB GTCB GTCB GTCB GTCB GTCB GTCB GTCB GTCB GTCB GTCB GTCB GTCB GTCB GTCB GTCB GTCB GTCB GTCB GTCB GTCB GTCB GTCB GTCB GTCB GTCB GTCB GTCB GTCB [/quote]
[quote=SkySpam1]
GTC Biotherapeutics and PharmAthene Extend Agreement for Protexia(R) Program
Thursday March 27, 7:30 am ET
biz.yahoo.com/bw/080327/2008032700528...FRAMINGHAM, Mass.--(BUSINESS WIRE)--GTC Biotherapeutics, Inc. ("GTC", Nasdaq: GTCB) has entered into an extended agreement with PharmAthene, Inc. (Amex: PIP - News) under which GTC will provide continuing process development and clinical supply manufacturing services for PharmAthene’s Protexia® program. The manufacturing work is planned to conclude in the third quarter of 2008. Protexia® is a recombinant form of human butyrylcholinesterase (rBChE) produced in the milk of transgenic goats, which is being developed by PharmAthene as a pre- and post-exposure therapy for victims of a chemical nerve agent attack.
“We are pleased to continue to support PharmAthene as it develops Protexia®,” stated Geoffrey F. Cox, Ph.D., GTC’s Chairman and Chief Executive Officer. “The constraint in supplying BChE from either human plasma sources or other recombinant systems is an excellent example of transgenic production enabling development of otherwise difficult to express proteins.”
While the utility of human plasma derived butyrylcholinesterase (BChE) to protect against nerve agent toxicity is well documented, a major limitation hindering its commercial development has been the inability to produce commercial quantities due to a limited availability of appropriate blood supplies, low levels of the protein in plasma, and low production yields using traditional biotechnology methods. Protexia® overcomes these limitations by enabling substantially larger production yields than are possible using other expression systems or through purification of the native protein from human plasma. Transgenic production and manufacturing is estimated to be capable of supplying sufficient rBChE to make Protexia® available for use by the military and civilian populations.
[/quote]
[quote=rac69]
wat doet die onzin van gtcb hier op dit draadje?...dat hoort hier toch niet thuis